25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Galectin Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Galectin Therapeutics Inc together

I guess you are interested in Galectin Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Galectin Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Galectin Therapeutics Inc

I send you an email if I find something interesting about Galectin Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Galectin Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Galectin Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
12.9%

What is your share worth?

Current worth
€-1.25
Expected worth in 1 year
€-1.72
How sure are you?
19.4%

+ What do you gain per year?

Total Gains per Share
€-0.47
Return On Investment
-17.3%

For what price can you sell your share?

Current Price per Share
€2.72
Expected price per share
€2.2 - €3.4
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Galectin Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
€2.72
Intrinsic Value Per Share
€-5.34 - €-6.22
Total Value Per Share
€-6.59 - €-7.47

2.2. Growth of Galectin Therapeutics Inc (5 min.)




Is Galectin Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$82.1m-$37m-$29m-43.9%

How much money is Galectin Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$11m-$9.9m-$1.1m-10.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Galectin Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#939 / 959

Most Revenue
#743 / 959

Most Profit
#587 / 959

Most Efficient
#810 / 959
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Galectin Therapeutics Inc?

Welcome investor! Galectin Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Galectin Therapeutics Inc.

First you should know what it really means to hold a share of Galectin Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Galectin Therapeutics Inc is €2.72. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galectin Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galectin Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-1.25. Based on the TTM, the Book Value Change Per Share is €-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galectin Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.20-7.3%-0.18-6.5%-0.16-5.9%-0.13-4.9%-0.11-4.1%
Usd Book Value Change Per Share-0.18-6.5%-0.12-4.6%-0.14-5.3%-0.11-3.9%-0.04-1.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.18-6.5%-0.12-4.6%-0.14-5.3%-0.11-3.9%-0.04-1.5%
Usd Price Per Share2.20-1.96-1.56-2.14-2.54-
Price to Earnings Ratio-2.77--2.74--2.45--4.97--7.73-
Price-to-Total Gains Ratio-12.37-103.13--11.07--8.54-4.61-
Price to Book Ratio-1.67--1.87--2.91-3.68-16.87-
Price-to-Total Gains Ratio-12.37-103.13--11.07--8.54-4.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.873952
Number of shares347
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.12-0.11
Usd Total Gains Per Share-0.12-0.11
Gains per Quarter (347 shares)-43.21-37.16
Gains per Year (347 shares)-172.83-148.62
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-173-1830-149-159
20-346-3561-298-308
30-518-5291-447-457
40-691-7022-596-606
50-864-8752-745-755
60-1037-10483-894-904
70-1210-12213-1043-1053
80-1383-13944-1192-1202
90-1555-15674-1342-1351
100-1728-17404-1491-1500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.031.00.00.0%0.031.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%5.026.00.016.1%5.026.00.016.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%4.00.027.012.9%4.00.027.012.9%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%6.025.00.019.4%6.025.00.019.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Galectin Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.168-0.118-30%-0.136-19%-0.102-40%-0.040-76%
Book Value Per Share---1.248-1.004-20%-0.563-55%-0.119-90%-0.019-99%
Current Ratio--1.8671.926-3%1.754+6%8.042-77%7.817-76%
Debt To Asset Ratio--3.9703.537+12%2.853+39%1.560+155%1.116+256%
Debt To Equity Ratio----0%-0%0.992-100%3.682-100%
Dividend Per Share----0%-0%0.000-100%0.001-100%
Eps---0.188-0.168-11%-0.152-19%-0.126-33%-0.106-44%
Free Cash Flow Per Share---0.127-0.125-2%-0.138+9%-0.109-14%-0.109-14%
Free Cash Flow To Equity Per Share--0.0310.029+7%0.014+116%0.033-5%0.033-5%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.221--------
Intrinsic Value_10Y_min---5.342--------
Intrinsic Value_1Y_max---0.509--------
Intrinsic Value_1Y_min---0.500--------
Intrinsic Value_3Y_max---1.616--------
Intrinsic Value_3Y_min---1.541--------
Intrinsic Value_5Y_max---2.828--------
Intrinsic Value_5Y_min---2.618--------
Market Cap169396432.000+24%129538500.000115525888.500+12%91704502.250+41%125895181.750+3%149577935.081-13%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-2.179-31%-1.666-1.872+12%-2.910+75%3.677-145%16.870-110%
Pe Ratio-3.617-31%-2.766-2.744-1%-2.454-11%-4.973+80%-7.727+179%
Price Per Share2.720+24%2.0801.855+12%1.473+41%2.022+3%2.402-13%
Price To Free Cash Flow Ratio-5.370-31%-4.106-3.960-4%-2.676-35%-4.712+15%-3.040-26%
Price To Total Gains Ratio-16.182-31%-12.375103.134-112%-11.066-11%-8.545-31%4.607-369%
Quick Ratio----0%-0%-0%-0%
Return On Assets---0.447-0.429-4%-0.501+12%-0.307-31%-0.343-23%
Return On Equity----0%-0%-0.2730%-5.3060%
Total Gains Per Share---0.168-0.118-30%-0.136-19%-0.101-40%-0.039-77%
Usd Book Value---82144226.717-66084518.911-20%-37074248.331-55%-7813436.209-90%-1231893.894-99%
Usd Book Value Change Per Share---0.178-0.125-30%-0.144-19%-0.107-40%-0.043-76%
Usd Book Value Per Share---1.319-1.061-20%-0.595-55%-0.125-90%-0.020-99%
Usd Dividend Per Share----0%-0%0.000-100%0.001-100%
Usd Eps---0.199-0.178-11%-0.160-19%-0.133-33%-0.112-44%
Usd Free Cash Flow---8332718.678-8193973.362-2%-9052694.371+9%-6468181.627-22%-4173020.404-50%
Usd Free Cash Flow Per Share---0.134-0.132-2%-0.145+9%-0.115-14%-0.115-14%
Usd Free Cash Flow To Equity Per Share--0.0330.031+7%0.015+116%0.034-5%0.034-5%
Usd Market Cap178984270.051+24%136870379.100122064653.789+12%96894977.077+41%133020849.037+3%158044046.206-13%
Usd Price Per Share2.874+24%2.1981.960+12%1.556+41%2.136+3%2.538-13%
Usd Profit---12370582.355-11070876.235-11%-9967663.480-19%-8280520.440-33%-6635743.712-46%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.178-0.125-30%-0.144-19%-0.107-40%-0.042-77%
 EOD+6 -2MRQTTM+7 -19YOY+12 -145Y+5 -2410Y+4 -25

3.3 Fundamental Score

Let's check the fundamental score of Galectin Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.617
Price to Book Ratio (EOD)Between0-1-2.179
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.867
Debt to Asset Ratio (MRQ)Less than13.970
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.447
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Galectin Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.986
Ma 20Greater thanMa 502.433
Ma 50Greater thanMa 1002.408
Ma 100Greater thanMa 2002.264
OpenGreater thanClose2.760
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Fundamental data was last updated by Penke on 2024-10-31 11:17:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Galectin Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galectin Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--133.6%+133.6%
TTM--204.9%+204.9%
YOY--207.4%+207.4%
5Y--353.5%+353.5%
10Y--466.1%+466.1%
4.3.1.2. Return on Assets

Shows how efficient Galectin Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • -44.7% Return on Assets means that Galectin Therapeutics Inc generated €-0.45 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galectin Therapeutics Inc:

  • The MRQ is -44.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.7%TTM-42.9%-1.8%
TTM-42.9%YOY-50.1%+7.2%
TTM-42.9%5Y-30.7%-12.2%
5Y-30.7%10Y-34.3%+3.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.7%-10.8%-33.9%
TTM-42.9%-11.8%-31.1%
YOY-50.1%-11.0%-39.1%
5Y-30.7%-12.6%-18.1%
10Y-34.3%-14.4%-19.9%
4.3.1.3. Return on Equity

Shows how efficient Galectin Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Galectin Therapeutics Inc generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galectin Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-27.3%+27.3%
5Y-27.3%10Y-530.6%+503.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM--15.9%+15.9%
YOY--13.5%+13.5%
5Y-27.3%-18.6%-8.7%
10Y-530.6%-19.0%-511.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Galectin Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Galectin Therapeutics Inc is operating .

  • Measures how much profit Galectin Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galectin Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--277.1%+277.1%
TTM--312.9%+312.9%
YOY--222.0%+222.0%
5Y--385.5%+385.5%
10Y--495.6%+495.6%
4.3.2.2. Operating Ratio

Measures how efficient Galectin Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Galectin Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.842-2.842
TTM-3.198-3.198
YOY-3.301-3.301
5Y-4.800-4.800
10Y-6.530-6.530
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Galectin Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Galectin Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.87 means the company has €1.87 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Galectin Therapeutics Inc:

  • The MRQ is 1.867. The company is able to pay all its short-term debts. +1
  • The TTM is 1.926. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.867TTM1.926-0.059
TTM1.926YOY1.754+0.172
TTM1.9265Y8.042-6.116
5Y8.04210Y7.817+0.226
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8673.788-1.921
TTM1.9263.923-1.997
YOY1.7544.711-2.957
5Y8.0425.959+2.083
10Y7.8176.278+1.539
4.4.3.2. Quick Ratio

Measures if Galectin Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off €0.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galectin Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.381-3.381
TTM-3.526-3.526
YOY-4.682-4.682
5Y-5.922-5.922
10Y-6.458-6.458
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Galectin Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Galectin Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Galectin Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.97 means that Galectin Therapeutics Inc assets are financed with 397.0% credit (debt) and the remaining percentage (100% - 397.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Galectin Therapeutics Inc:

  • The MRQ is 3.970. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 3.537. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.970TTM3.537+0.433
TTM3.537YOY2.853+0.683
TTM3.5375Y1.560+1.977
5Y1.56010Y1.116+0.444
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9700.338+3.632
TTM3.5370.347+3.190
YOY2.8530.310+2.543
5Y1.5600.365+1.195
10Y1.1160.381+0.735
4.5.4.2. Debt to Equity Ratio

Measures if Galectin Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galectin Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.992-0.992
5Y0.99210Y3.682-2.689
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.387-0.387
TTM-0.437-0.437
YOY-0.375-0.375
5Y0.9920.450+0.542
10Y3.6820.489+3.193
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Galectin Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Galectin Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.77 means the investor is paying €-2.77 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galectin Therapeutics Inc:

  • The EOD is -3.617. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.766. Based on the earnings, the company is expensive. -2
  • The TTM is -2.744. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.617MRQ-2.766-0.851
MRQ-2.766TTM-2.744-0.022
TTM-2.744YOY-2.454-0.289
TTM-2.7445Y-4.973+2.229
5Y-4.97310Y-7.727+2.754
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.617-2.384-1.233
MRQ-2.766-2.428-0.338
TTM-2.744-2.991+0.247
YOY-2.454-3.440+0.986
5Y-4.973-6.006+1.033
10Y-7.727-6.278-1.449
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galectin Therapeutics Inc:

  • The EOD is -5.370. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.106. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.960. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.370MRQ-4.106-1.264
MRQ-4.106TTM-3.960-0.146
TTM-3.960YOY-2.676-1.284
TTM-3.9605Y-4.712+0.752
5Y-4.71210Y-3.040-1.672
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.370-3.160-2.210
MRQ-4.106-3.222-0.884
TTM-3.960-3.516-0.444
YOY-2.676-4.582+1.906
5Y-4.712-8.076+3.364
10Y-3.040-8.950+5.910
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Galectin Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.67 means the investor is paying €-1.67 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Galectin Therapeutics Inc:

  • The EOD is -2.179. Based on the equity, the company is expensive. -2
  • The MRQ is -1.666. Based on the equity, the company is expensive. -2
  • The TTM is -1.872. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.179MRQ-1.666-0.513
MRQ-1.666TTM-1.872+0.206
TTM-1.872YOY-2.910+1.038
TTM-1.8725Y3.677-5.549
5Y3.67710Y16.870-13.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.1791.964-4.143
MRQ-1.6661.983-3.649
TTM-1.8722.197-4.069
YOY-2.9102.404-5.314
5Y3.6773.596+0.081
10Y16.8704.223+12.647
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets27,655
Total Liabilities109,802
Total Stockholder Equity-82,147
 As reported
Total Liabilities 109,802
Total Stockholder Equity+ -82,147
Total Assets = 27,655

Assets

Total Assets27,655
Total Current Assets27,287
Long-term Assets368
Total Current Assets
Cash And Cash Equivalents 25,598
Other Current Assets 1,689
Total Current Assets  (as reported)27,287
Total Current Assets  (calculated)27,287
+/-0
Long-term Assets
Long-term Assets Other 368
Long-term Assets  (as reported)368
Long-term Assets  (calculated)368
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,617
Long-term Liabilities95,185
Total Stockholder Equity-82,147
Total Current Liabilities
Accounts payable 3,698
Total Current Liabilities  (as reported)14,617
Total Current Liabilities  (calculated)3,698
+/- 10,919
Long-term Liabilities
Long term Debt 93,421
Capital Lease Obligations Min Short Term Debt44
Long-term Liabilities  (as reported)95,185
Long-term Liabilities  (calculated)93,465
+/- 1,720
Total Stockholder Equity
Total Stockholder Equity (as reported)-82,147
Total Stockholder Equity (calculated)0
+/- 82,147
Other
Capital Stock2,285
Common Stock Shares Outstanding 62,278
Net Debt 67,823
Net Invested Capital 9,051
Net Working Capital 12,670



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
15,795
13,997
9,329
7,011
4,161
4,931
11,210
10,616
9,006
7,830
53,012
50,760
48,467
44,111
41,317
34,049
29,600
22,897
33,405
38,038
41,827
33,615
25,886
17,914
21,285
20,225
20,081
22,163
28,200
25,890
27,655
27,65525,89028,20022,16320,08120,22521,28517,91425,88633,61541,82738,03833,40522,89729,60034,04941,31744,11148,46750,76053,0127,8309,00610,61611,2104,9314,1617,0119,32913,99715,795
   > Total Current Assets 
15,794
13,997
9,329
7,011
3,819
4,673
11,038
10,530
8,832
7,483
52,695
50,473
48,209
43,884
41,120
33,883
29,465
22,794
33,334
37,998
41,820
33,507
25,785
17,121
20,552
19,552
19,468
21,611
27,710
25,460
27,287
27,28725,46027,71021,61119,46819,55220,55217,12125,78533,50741,82037,99833,33422,79429,46533,88341,12043,88448,20950,47352,6957,4838,83210,53011,0384,6733,8197,0119,32913,99715,794
       Cash And Cash Equivalents 
15,362
13,644
9,127
6,958
3,053
3,988
10,497
10,136
8,253
6,972
52,043
50,337
47,480
43,328
40,768
32,556
27,142
20,760
31,598
36,600
39,648
31,606
24,178
15,831
18,592
17,799
17,966
20,362
25,660
23,555
25,598
25,59823,55525,66020,36217,96617,79918,59215,83124,17831,60639,64836,60031,59820,76027,14232,55640,76843,32847,48050,33752,0436,9728,25310,13610,4973,9883,0536,9589,12713,64415,362
       Other Current Assets 
432
353
202
53
6
685
0
0
6
0
0
0
6
0
0
0
6
0
0
0
6
1,901
1,607
1,290
1,960
1,753
1,502
1,249
2,050
1,905
1,689
1,6891,9052,0501,2491,5021,7531,9601,2901,6071,901600060006000600685653202353432
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
347
317
287
258
227
197
166
135
103
71
40
7
108
101
793
733
673
613
552
490
430
368
36843049055261367373379310110874071103135166197227258287317347000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
108
101
92
84
75
66
57
48
38
28
18
7
108
101
793
733
673
0
0
74
0
0
0074006737337931011087182838485766758492101108000000000
       Intangible Assets 
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000001
       Other Assets 
0
0
0
0
342
258
172
86
174
239
216
195
174
152
131
109
87
65
43
22
0
108
101
700
733
673
0
0
0
0
0
00000673733700101108022436587109131152174195216239174861722583420000
> Total Liabilities 
3,780
4,362
3,512
4,341
2,968
2,283
1,435
1,646
2,108
988
1,391
1,278
2,872
1,358
4,306
2,507
5,407
4,663
16,289
28,789
39,211
39,808
41,109
40,249
53,479
62,871
71,208
73,036
88,441
96,976
109,802
109,80296,97688,44173,03671,20862,87153,47940,24941,10939,80839,21128,78916,2894,6635,4072,5074,3061,3582,8721,2781,3919882,1081,6461,4352,2832,9684,3413,5124,3623,780
   > Total Current Liabilities 
3,780
4,362
3,512
4,341
2,968
2,283
1,435
1,646
2,108
907
1,319
1,216
2,820
1,316
4,275
2,488
5,399
4,663
6,054
8,299
9,033
9,535
10,892
9,588
13,012
11,533
9,953
10,522
15,676
12,633
14,617
14,61712,63315,67610,5229,95311,53313,0129,58810,8929,5359,0338,2996,0544,6635,3992,4884,2751,3162,8201,2161,3199072,1081,6461,4352,2832,9684,3413,5124,3623,780
       Short-term Debt 
0
0
0
0
0
0
0
0
0
34
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000034000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
34
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000034000000000
       Accounts payable 
3,780
4,362
399
166
608
1,151
220
171
297
448
396
354
1,661
660
206
691
1,292
382
924
1,917
1,805
1,906
2,964
2,352
3,890
2,553
1,976
2,681
6,431
3,797
3,698
3,6983,7976,4312,6811,9762,5533,8902,3522,9641,9061,8051,9179243821,2926912066601,6613543964482971712201,1516081663994,3623,780
       Other Current Liabilities 
0
0
68
0
68
0
67
0
299
34
66
0
66
0
66
0
65
0
65
0
65
0
64
0
64
0
0
0
0
0
0
000000640640650650650660660663429906706806800
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
81
72
62
52
42
31
19
8
0
10,235
20,490
30,178
30,273
30,217
30,661
40,467
51,338
61,255
62,514
72,765
84,343
95,185
95,18584,34372,76562,51461,25551,33840,46730,66130,21730,27330,17820,49010,2350819314252627281000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
62
52
1
31
0
8
0
592
0
0
97
87
77
66
55
0
0
0
0
0
00000556677879700592080311526200000000000
> Total Stockholder Equity
10,292
7,912
-3,145
-6,292
-7,769
-6,314
823
18
-2,044
6,842
51,621
49,482
45,595
42,753
37,011
31,542
24,193
18,234
17,116
9,249
2,616
-6,193
-15,223
-22,335
-32,194
-42,646
-51,127
-50,873
-60,241
-71,086
-82,147
-82,147-71,086-60,241-50,873-51,127-42,646-32,194-22,335-15,223-6,1932,6169,24917,11618,23424,19331,54237,01142,75345,59549,48251,6216,842-2,04418823-6,314-7,769-6,292-3,1457,91210,292
   Common Stock
33
35
35
36
36
38
41
41
41
45
56
56
56
56
56
56
56
56
59
59
59
59
59
59
59
59
0
0
0
0
0
000005959595959595959565656565656565645414141383636353533
   Retained Earnings Total Equity0000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 0000000000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-38,072
Operating Income-38,072-38,072
 
Operating Expense (+$)
Research Development32,130
Selling General Administrative5,942
Selling And Marketing Expenses-
Operating Expense38,07238,072
 
Net Interest Income (+$)
Interest Income230
Interest Expense-2,792
Other Finance Cost-0
Net Interest Income-2,562
 
Pretax Income (+$)
Operating Income-38,072
Net Interest Income-2,562
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-41,066-37,640
EBIT - interestExpense = -2,792
-41,066
-38,274
Interest Expense2,792
Earnings Before Interest and Taxes (EBIT)--38,274
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-41,066
Tax Provision--
Net Income From Continuing Ops-41,066-41,066
Net Income-41,066
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-4322,562
 

Technical Analysis of Galectin Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Galectin Therapeutics Inc. The general trend of Galectin Therapeutics Inc is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Galectin Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Galectin Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.94 < 2.94 < 3.4.

The bearish price targets are: 2.6 > 2.44 > 2.2.

Tweet this
Galectin Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Galectin Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Galectin Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Galectin Therapeutics Inc. The current macd is 0.08988313.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Galectin Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Galectin Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Galectin Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Galectin Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartGalectin Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Galectin Therapeutics Inc. The current adx is 28.90.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Galectin Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Galectin Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Galectin Therapeutics Inc. The current sar is 2.3348651.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Galectin Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Galectin Therapeutics Inc. The current rsi is 67.99. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Galectin Therapeutics Inc Daily Relative Strength Index (RSI) ChartGalectin Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Galectin Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Galectin Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Galectin Therapeutics Inc Daily Stochastic Oscillator ChartGalectin Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Galectin Therapeutics Inc. The current cci is 143.08.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Galectin Therapeutics Inc Daily Commodity Channel Index (CCI) ChartGalectin Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Galectin Therapeutics Inc. The current cmo is 45.27.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Galectin Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartGalectin Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Galectin Therapeutics Inc. The current willr is -10.34482759.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Galectin Therapeutics Inc Daily Williams %R ChartGalectin Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Galectin Therapeutics Inc.

Galectin Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Galectin Therapeutics Inc. The current atr is 0.06954938.

Galectin Therapeutics Inc Daily Average True Range (ATR) ChartGalectin Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Galectin Therapeutics Inc. The current obv is -13,256.

Galectin Therapeutics Inc Daily On-Balance Volume (OBV) ChartGalectin Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Galectin Therapeutics Inc. The current mfi is 3.58025822.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Galectin Therapeutics Inc Daily Money Flow Index (MFI) ChartGalectin Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Galectin Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-02 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-05 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-08 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-09 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-11 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-16 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-31 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-01 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-02 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-19 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-21 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-27 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-28 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-29 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-04 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-12 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-13 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-20 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-24 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-10 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-23 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-28 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-29 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside

6.3. Candlestick Patterns

Galectin Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Galectin Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.986
Ma 20Greater thanMa 502.433
Ma 50Greater thanMa 1002.408
Ma 100Greater thanMa 2002.264
OpenGreater thanClose2.760
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Galectin Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Galectin Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Galectin Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Galectin Therapeutics Inc

I send you an email if I find something interesting about Galectin Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Galectin Therapeutics Inc.

Receive notifications about Galectin Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.